Illuminati Press
Latest news from around the world.

Bharat Biotech’s Covaxin Gets Emergency Use Authorisation For Children Aged 6-12: Sources

0


The Drugs Controller General of India has given restricted emergency use authorisation to BharatBiotech’s Covaxin for children between the age of 6-12 years, according to sources.

This development comes following recommendations by the Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation(CDSCO).

The SEC had last week reviewed the application of both the companies seeking emergency use authorisation for Corbevax and Covaxin for use in children of five to 12 years and six to 12 years age group, respectively.

Biological E’s Corbevax is being used to inoculate children against Covid-19 in the age group of 12 to 14 years. Covaxin has been granted Emergency Use Listing (EUL) by the DCGI for the age group of 12 to 18 years on December 24, 2021.

India began inoculating children aged 12-14 on March 16. The countrywide vaccination drive was rolled out on January 16 last year with healthcare workers getting inoculated in the first phase. Vaccination of frontline workers started from February 2 last year.

The next phase of Covid-19 vaccination commenced on March 1 last year for people over 60 years of age and those aged 45 and above with specified co-morbid conditions.

India launched vaccination for all people aged more than 45 years from April 1 last year. The government then decided to expand its vaccination drive by allowing everyone above 18 years of age to be inoculated against the viral disease from May 1 last year.

The next phase of vaccination commenced on January 3 for adolescents in the age group of 15-18 years.

India began administering precaution doses of vaccines to healthcare and frontline workers and those aged 60 and above with comorbidities from January 10.

Precaution doses of Covid-19 vaccines to all aged above 18 years were allowed at private vaccination centres from April 10.

(With inputs from agencies)

 

 

Subscribe to Mint Newsletters

* Enter a valid email

* Thank you for subscribing to our newsletter.



Source link

Leave A Reply

Your email address will not be published.